Effectiveness of mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections during the SARS-CoV-2 Omicron BA.1 and BA.2 epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS)
Evaluating COVID-19 vaccine effectiveness (VE) domestically is crucial for assessing and determining national vaccination policy. This study aimed to evaluate VE of mRNA COVID-19 vaccines in Japan. We conducted a multicenter test-negative case-control study. The study comprised individuals aged ≥16...
Gespeichert in:
| Veröffentlicht in: | Expert review of vaccines 2023-12, Vol.22 (1), p.288-298 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 298 |
|---|---|
| container_issue | 1 |
| container_start_page | 288 |
| container_title | Expert review of vaccines |
| container_volume | 22 |
| creator | Maeda, Haruka Saito, Nobuo Igarashi, Ataru Ishida, Masayuki Terada, Mayumi Ito, Takayasu Ikeda, Hideko Kamura, Hiroshi Motohashi, Iori Kimura, Yuya Komino, Masaru Arai, Hiromi Kuwamitsu, Osamu Akuzawa, Nobuhiro Sando, Eiichiro Morikawa, Toru Imura, Haruki Inoue, Hiroki Hayakawa, Tomoichiro Teshigahara, Osamu Ohara, Yasuji Suzuki, Motoi Morimoto, Konosuke |
| description | Evaluating COVID-19 vaccine effectiveness (VE) domestically is crucial for assessing and determining national vaccination policy. This study aimed to evaluate VE of mRNA COVID-19 vaccines in Japan.
We conducted a multicenter test-negative case-control study. The study comprised individuals aged ≥16 visiting medical facilities with COVID-19-related signs or symptoms from 1 January to 26 June 2022, when Omicron BA.1 and BA.2 were dominant nationwide. We evaluated VE of primary and booster vaccination against symptomatic SARS-CoV-2 infections and relative VE of booster compared with primary.
We enrolled 7,931 episodes, including 3,055 test positive. The median age was 39, 48.0% were male, and 20.5% had underlying medical conditions. In individuals aged 16 to 64, VE of primary vaccination within 90 days was 35.6% (95% CI, 19.0-48.8%). After booster, VE increased to 68.7% (60.6-75.1%). In individuals aged ≥65, VE of primary and booster was 31.2% (−44.0-67.1%) and 76.5% (46.7-89.7%), respectively. Relative VE of booster compared with primary vaccination was 52.9% (41.0-62.5%) in individuals aged 16 to 64 and 65.9% (35.7-81.9%) in individuals aged ≥65.
During BA.1 and BA.2 epidemic in Japan, mRNA COVID-19 primary vaccination provided modest protection. Booster vaccination was necessary to protect against symptomatic infections. |
| doi_str_mv | 10.1080/14760584.2023.2188950 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1080_14760584_2023_2188950</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_c5e2c260b54845e1b8297de267718e84</doaj_id><sourcerecordid>2784839263</sourcerecordid><originalsourceid>FETCH-LOGICAL-c523t-242a002d888999c049524932cff76c0ac4b962b19be9a09455196008c4b34e463</originalsourceid><addsrcrecordid>eNp9Uk2P0zAUjBCIXRZ-AsjH5ZDiz8TmRCkFilZUatleLcd5KV4lcbHTov5Q_g_utl0tF05-8ps3Y8-bLHtN8Ihgid8RXhZYSD6imLIRJVIqgZ9kl6TkPJdMiaepTpj8ALrIXsR4hzHjSpTPswtWSMlYSS6zP9OmATu4HfQQI_IN6hbfx2gyX80-5UShnbHWpRYya-P6OKC47zaD78zgLFqOF8t84lc5Ra6_p_F9RPU2uH6Nhp_wGDDvnA2-Rx_HI4JMXx8KimDjakidNI--mY3p358VEfzzsACmzQfXAYrbsAPXtqa3gBofHotcr6aL5e3y7cvsWWPaCK9O51V2-3n6Y_I1v5l_mU3GN7kVlA055dRgTGuZzFPK4uQO5YpR2zRlYbGxvFIFrYiqQBmsuBBEFRjLdM848IJdZbMjb-3Nnd4E15mw1944fX_hw1qbkJxqQVsB1NICV4JLLoBUkqqyBlqUJZEgeeK6PnJtgv-1hTjozkULh4-C30ZNS8nTXmnBElQcocnRGAM0D9IE60M69Dkd-pAOfUpHmntzkthWHdQPU-c4JMCHIyCt04fO_PahrfVg9q0PTUiOu6jZ_zX-AqzTxVU</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2784839263</pqid></control><display><type>article</type><title>Effectiveness of mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections during the SARS-CoV-2 Omicron BA.1 and BA.2 epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS)</title><source>Taylor & Francis Open Access</source><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><creator>Maeda, Haruka ; Saito, Nobuo ; Igarashi, Ataru ; Ishida, Masayuki ; Terada, Mayumi ; Ito, Takayasu ; Ikeda, Hideko ; Kamura, Hiroshi ; Motohashi, Iori ; Kimura, Yuya ; Komino, Masaru ; Arai, Hiromi ; Kuwamitsu, Osamu ; Akuzawa, Nobuhiro ; Sando, Eiichiro ; Morikawa, Toru ; Imura, Haruki ; Inoue, Hiroki ; Hayakawa, Tomoichiro ; Teshigahara, Osamu ; Ohara, Yasuji ; Suzuki, Motoi ; Morimoto, Konosuke</creator><creatorcontrib>Maeda, Haruka ; Saito, Nobuo ; Igarashi, Ataru ; Ishida, Masayuki ; Terada, Mayumi ; Ito, Takayasu ; Ikeda, Hideko ; Kamura, Hiroshi ; Motohashi, Iori ; Kimura, Yuya ; Komino, Masaru ; Arai, Hiromi ; Kuwamitsu, Osamu ; Akuzawa, Nobuhiro ; Sando, Eiichiro ; Morikawa, Toru ; Imura, Haruki ; Inoue, Hiroki ; Hayakawa, Tomoichiro ; Teshigahara, Osamu ; Ohara, Yasuji ; Suzuki, Motoi ; Morimoto, Konosuke</creatorcontrib><description>Evaluating COVID-19 vaccine effectiveness (VE) domestically is crucial for assessing and determining national vaccination policy. This study aimed to evaluate VE of mRNA COVID-19 vaccines in Japan.
We conducted a multicenter test-negative case-control study. The study comprised individuals aged ≥16 visiting medical facilities with COVID-19-related signs or symptoms from 1 January to 26 June 2022, when Omicron BA.1 and BA.2 were dominant nationwide. We evaluated VE of primary and booster vaccination against symptomatic SARS-CoV-2 infections and relative VE of booster compared with primary.
We enrolled 7,931 episodes, including 3,055 test positive. The median age was 39, 48.0% were male, and 20.5% had underlying medical conditions. In individuals aged 16 to 64, VE of primary vaccination within 90 days was 35.6% (95% CI, 19.0-48.8%). After booster, VE increased to 68.7% (60.6-75.1%). In individuals aged ≥65, VE of primary and booster was 31.2% (−44.0-67.1%) and 76.5% (46.7-89.7%), respectively. Relative VE of booster compared with primary vaccination was 52.9% (41.0-62.5%) in individuals aged 16 to 64 and 65.9% (35.7-81.9%) in individuals aged ≥65.
During BA.1 and BA.2 epidemic in Japan, mRNA COVID-19 primary vaccination provided modest protection. Booster vaccination was necessary to protect against symptomatic infections.</description><identifier>ISSN: 1476-0584</identifier><identifier>EISSN: 1744-8395</identifier><identifier>DOI: 10.1080/14760584.2023.2188950</identifier><identifier>PMID: 36883371</identifier><language>eng</language><publisher>England: Taylor & Francis</publisher><subject>BA.1 ; BA.2 ; Case-Control Studies ; COVID-19 - epidemiology ; COVID-19 - prevention & control ; COVID-19 Vaccines ; COVID19 ; Female ; Humans ; Japan ; Japan - epidemiology ; Male ; omicron ; RNA, Messenger ; SARS-CoV-2 - genetics ; SARSCoV2 ; vaccine effectiveness ; Vaccine Efficacy</subject><ispartof>Expert review of vaccines, 2023-12, Vol.22 (1), p.288-298</ispartof><rights>2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c523t-242a002d888999c049524932cff76c0ac4b962b19be9a09455196008c4b34e463</citedby><cites>FETCH-LOGICAL-c523t-242a002d888999c049524932cff76c0ac4b962b19be9a09455196008c4b34e463</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.tandfonline.com/doi/pdf/10.1080/14760584.2023.2188950$$EPDF$$P50$$Ginformaworld$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.tandfonline.com/doi/full/10.1080/14760584.2023.2188950$$EHTML$$P50$$Ginformaworld$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,860,2096,27479,27901,27902,59116,59117</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36883371$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Maeda, Haruka</creatorcontrib><creatorcontrib>Saito, Nobuo</creatorcontrib><creatorcontrib>Igarashi, Ataru</creatorcontrib><creatorcontrib>Ishida, Masayuki</creatorcontrib><creatorcontrib>Terada, Mayumi</creatorcontrib><creatorcontrib>Ito, Takayasu</creatorcontrib><creatorcontrib>Ikeda, Hideko</creatorcontrib><creatorcontrib>Kamura, Hiroshi</creatorcontrib><creatorcontrib>Motohashi, Iori</creatorcontrib><creatorcontrib>Kimura, Yuya</creatorcontrib><creatorcontrib>Komino, Masaru</creatorcontrib><creatorcontrib>Arai, Hiromi</creatorcontrib><creatorcontrib>Kuwamitsu, Osamu</creatorcontrib><creatorcontrib>Akuzawa, Nobuhiro</creatorcontrib><creatorcontrib>Sando, Eiichiro</creatorcontrib><creatorcontrib>Morikawa, Toru</creatorcontrib><creatorcontrib>Imura, Haruki</creatorcontrib><creatorcontrib>Inoue, Hiroki</creatorcontrib><creatorcontrib>Hayakawa, Tomoichiro</creatorcontrib><creatorcontrib>Teshigahara, Osamu</creatorcontrib><creatorcontrib>Ohara, Yasuji</creatorcontrib><creatorcontrib>Suzuki, Motoi</creatorcontrib><creatorcontrib>Morimoto, Konosuke</creatorcontrib><title>Effectiveness of mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections during the SARS-CoV-2 Omicron BA.1 and BA.2 epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS)</title><title>Expert review of vaccines</title><addtitle>Expert Rev Vaccines</addtitle><description>Evaluating COVID-19 vaccine effectiveness (VE) domestically is crucial for assessing and determining national vaccination policy. This study aimed to evaluate VE of mRNA COVID-19 vaccines in Japan.
We conducted a multicenter test-negative case-control study. The study comprised individuals aged ≥16 visiting medical facilities with COVID-19-related signs or symptoms from 1 January to 26 June 2022, when Omicron BA.1 and BA.2 were dominant nationwide. We evaluated VE of primary and booster vaccination against symptomatic SARS-CoV-2 infections and relative VE of booster compared with primary.
We enrolled 7,931 episodes, including 3,055 test positive. The median age was 39, 48.0% were male, and 20.5% had underlying medical conditions. In individuals aged 16 to 64, VE of primary vaccination within 90 days was 35.6% (95% CI, 19.0-48.8%). After booster, VE increased to 68.7% (60.6-75.1%). In individuals aged ≥65, VE of primary and booster was 31.2% (−44.0-67.1%) and 76.5% (46.7-89.7%), respectively. Relative VE of booster compared with primary vaccination was 52.9% (41.0-62.5%) in individuals aged 16 to 64 and 65.9% (35.7-81.9%) in individuals aged ≥65.
During BA.1 and BA.2 epidemic in Japan, mRNA COVID-19 primary vaccination provided modest protection. Booster vaccination was necessary to protect against symptomatic infections.</description><subject>BA.1</subject><subject>BA.2</subject><subject>Case-Control Studies</subject><subject>COVID-19 - epidemiology</subject><subject>COVID-19 - prevention & control</subject><subject>COVID-19 Vaccines</subject><subject>COVID19</subject><subject>Female</subject><subject>Humans</subject><subject>Japan</subject><subject>Japan - epidemiology</subject><subject>Male</subject><subject>omicron</subject><subject>RNA, Messenger</subject><subject>SARS-CoV-2 - genetics</subject><subject>SARSCoV2</subject><subject>vaccine effectiveness</subject><subject>Vaccine Efficacy</subject><issn>1476-0584</issn><issn>1744-8395</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>0YH</sourceid><sourceid>EIF</sourceid><sourceid>DOA</sourceid><recordid>eNp9Uk2P0zAUjBCIXRZ-AsjH5ZDiz8TmRCkFilZUatleLcd5KV4lcbHTov5Q_g_utl0tF05-8ps3Y8-bLHtN8Ihgid8RXhZYSD6imLIRJVIqgZ9kl6TkPJdMiaepTpj8ALrIXsR4hzHjSpTPswtWSMlYSS6zP9OmATu4HfQQI_IN6hbfx2gyX80-5UShnbHWpRYya-P6OKC47zaD78zgLFqOF8t84lc5Ra6_p_F9RPU2uH6Nhp_wGDDvnA2-Rx_HI4JMXx8KimDjakidNI--mY3p358VEfzzsACmzQfXAYrbsAPXtqa3gBofHotcr6aL5e3y7cvsWWPaCK9O51V2-3n6Y_I1v5l_mU3GN7kVlA055dRgTGuZzFPK4uQO5YpR2zRlYbGxvFIFrYiqQBmsuBBEFRjLdM848IJdZbMjb-3Nnd4E15mw1944fX_hw1qbkJxqQVsB1NICV4JLLoBUkqqyBlqUJZEgeeK6PnJtgv-1hTjozkULh4-C30ZNS8nTXmnBElQcocnRGAM0D9IE60M69Dkd-pAOfUpHmntzkthWHdQPU-c4JMCHIyCt04fO_PahrfVg9q0PTUiOu6jZ_zX-AqzTxVU</recordid><startdate>20231231</startdate><enddate>20231231</enddate><creator>Maeda, Haruka</creator><creator>Saito, Nobuo</creator><creator>Igarashi, Ataru</creator><creator>Ishida, Masayuki</creator><creator>Terada, Mayumi</creator><creator>Ito, Takayasu</creator><creator>Ikeda, Hideko</creator><creator>Kamura, Hiroshi</creator><creator>Motohashi, Iori</creator><creator>Kimura, Yuya</creator><creator>Komino, Masaru</creator><creator>Arai, Hiromi</creator><creator>Kuwamitsu, Osamu</creator><creator>Akuzawa, Nobuhiro</creator><creator>Sando, Eiichiro</creator><creator>Morikawa, Toru</creator><creator>Imura, Haruki</creator><creator>Inoue, Hiroki</creator><creator>Hayakawa, Tomoichiro</creator><creator>Teshigahara, Osamu</creator><creator>Ohara, Yasuji</creator><creator>Suzuki, Motoi</creator><creator>Morimoto, Konosuke</creator><general>Taylor & Francis</general><general>Taylor & Francis Group</general><scope>0YH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>DOA</scope></search><sort><creationdate>20231231</creationdate><title>Effectiveness of mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections during the SARS-CoV-2 Omicron BA.1 and BA.2 epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS)</title><author>Maeda, Haruka ; Saito, Nobuo ; Igarashi, Ataru ; Ishida, Masayuki ; Terada, Mayumi ; Ito, Takayasu ; Ikeda, Hideko ; Kamura, Hiroshi ; Motohashi, Iori ; Kimura, Yuya ; Komino, Masaru ; Arai, Hiromi ; Kuwamitsu, Osamu ; Akuzawa, Nobuhiro ; Sando, Eiichiro ; Morikawa, Toru ; Imura, Haruki ; Inoue, Hiroki ; Hayakawa, Tomoichiro ; Teshigahara, Osamu ; Ohara, Yasuji ; Suzuki, Motoi ; Morimoto, Konosuke</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c523t-242a002d888999c049524932cff76c0ac4b962b19be9a09455196008c4b34e463</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>BA.1</topic><topic>BA.2</topic><topic>Case-Control Studies</topic><topic>COVID-19 - epidemiology</topic><topic>COVID-19 - prevention & control</topic><topic>COVID-19 Vaccines</topic><topic>COVID19</topic><topic>Female</topic><topic>Humans</topic><topic>Japan</topic><topic>Japan - epidemiology</topic><topic>Male</topic><topic>omicron</topic><topic>RNA, Messenger</topic><topic>SARS-CoV-2 - genetics</topic><topic>SARSCoV2</topic><topic>vaccine effectiveness</topic><topic>Vaccine Efficacy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Maeda, Haruka</creatorcontrib><creatorcontrib>Saito, Nobuo</creatorcontrib><creatorcontrib>Igarashi, Ataru</creatorcontrib><creatorcontrib>Ishida, Masayuki</creatorcontrib><creatorcontrib>Terada, Mayumi</creatorcontrib><creatorcontrib>Ito, Takayasu</creatorcontrib><creatorcontrib>Ikeda, Hideko</creatorcontrib><creatorcontrib>Kamura, Hiroshi</creatorcontrib><creatorcontrib>Motohashi, Iori</creatorcontrib><creatorcontrib>Kimura, Yuya</creatorcontrib><creatorcontrib>Komino, Masaru</creatorcontrib><creatorcontrib>Arai, Hiromi</creatorcontrib><creatorcontrib>Kuwamitsu, Osamu</creatorcontrib><creatorcontrib>Akuzawa, Nobuhiro</creatorcontrib><creatorcontrib>Sando, Eiichiro</creatorcontrib><creatorcontrib>Morikawa, Toru</creatorcontrib><creatorcontrib>Imura, Haruki</creatorcontrib><creatorcontrib>Inoue, Hiroki</creatorcontrib><creatorcontrib>Hayakawa, Tomoichiro</creatorcontrib><creatorcontrib>Teshigahara, Osamu</creatorcontrib><creatorcontrib>Ohara, Yasuji</creatorcontrib><creatorcontrib>Suzuki, Motoi</creatorcontrib><creatorcontrib>Morimoto, Konosuke</creatorcontrib><collection>Taylor & Francis Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Expert review of vaccines</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Maeda, Haruka</au><au>Saito, Nobuo</au><au>Igarashi, Ataru</au><au>Ishida, Masayuki</au><au>Terada, Mayumi</au><au>Ito, Takayasu</au><au>Ikeda, Hideko</au><au>Kamura, Hiroshi</au><au>Motohashi, Iori</au><au>Kimura, Yuya</au><au>Komino, Masaru</au><au>Arai, Hiromi</au><au>Kuwamitsu, Osamu</au><au>Akuzawa, Nobuhiro</au><au>Sando, Eiichiro</au><au>Morikawa, Toru</au><au>Imura, Haruki</au><au>Inoue, Hiroki</au><au>Hayakawa, Tomoichiro</au><au>Teshigahara, Osamu</au><au>Ohara, Yasuji</au><au>Suzuki, Motoi</au><au>Morimoto, Konosuke</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effectiveness of mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections during the SARS-CoV-2 Omicron BA.1 and BA.2 epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS)</atitle><jtitle>Expert review of vaccines</jtitle><addtitle>Expert Rev Vaccines</addtitle><date>2023-12-31</date><risdate>2023</risdate><volume>22</volume><issue>1</issue><spage>288</spage><epage>298</epage><pages>288-298</pages><issn>1476-0584</issn><eissn>1744-8395</eissn><abstract>Evaluating COVID-19 vaccine effectiveness (VE) domestically is crucial for assessing and determining national vaccination policy. This study aimed to evaluate VE of mRNA COVID-19 vaccines in Japan.
We conducted a multicenter test-negative case-control study. The study comprised individuals aged ≥16 visiting medical facilities with COVID-19-related signs or symptoms from 1 January to 26 June 2022, when Omicron BA.1 and BA.2 were dominant nationwide. We evaluated VE of primary and booster vaccination against symptomatic SARS-CoV-2 infections and relative VE of booster compared with primary.
We enrolled 7,931 episodes, including 3,055 test positive. The median age was 39, 48.0% were male, and 20.5% had underlying medical conditions. In individuals aged 16 to 64, VE of primary vaccination within 90 days was 35.6% (95% CI, 19.0-48.8%). After booster, VE increased to 68.7% (60.6-75.1%). In individuals aged ≥65, VE of primary and booster was 31.2% (−44.0-67.1%) and 76.5% (46.7-89.7%), respectively. Relative VE of booster compared with primary vaccination was 52.9% (41.0-62.5%) in individuals aged 16 to 64 and 65.9% (35.7-81.9%) in individuals aged ≥65.
During BA.1 and BA.2 epidemic in Japan, mRNA COVID-19 primary vaccination provided modest protection. Booster vaccination was necessary to protect against symptomatic infections.</abstract><cop>England</cop><pub>Taylor & Francis</pub><pmid>36883371</pmid><doi>10.1080/14760584.2023.2188950</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1476-0584 |
| ispartof | Expert review of vaccines, 2023-12, Vol.22 (1), p.288-298 |
| issn | 1476-0584 1744-8395 |
| language | eng |
| recordid | cdi_crossref_primary_10_1080_14760584_2023_2188950 |
| source | Taylor & Francis Open Access; MEDLINE; DOAJ Directory of Open Access Journals |
| subjects | BA.1 BA.2 Case-Control Studies COVID-19 - epidemiology COVID-19 - prevention & control COVID-19 Vaccines COVID19 Female Humans Japan Japan - epidemiology Male omicron RNA, Messenger SARS-CoV-2 - genetics SARSCoV2 vaccine effectiveness Vaccine Efficacy |
| title | Effectiveness of mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections during the SARS-CoV-2 Omicron BA.1 and BA.2 epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T02%3A28%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effectiveness%20of%20mRNA%20COVID-19%20vaccines%20against%20symptomatic%20SARS-CoV-2%20infections%20during%20the%20SARS-CoV-2%20Omicron%20BA.1%20and%20BA.2%20epidemic%20in%20Japan:%20vaccine%20effectiveness%20real-time%20surveillance%20for%20SARS-CoV-2%20(VERSUS)&rft.jtitle=Expert%20review%20of%20vaccines&rft.au=Maeda,%20Haruka&rft.date=2023-12-31&rft.volume=22&rft.issue=1&rft.spage=288&rft.epage=298&rft.pages=288-298&rft.issn=1476-0584&rft.eissn=1744-8395&rft_id=info:doi/10.1080/14760584.2023.2188950&rft_dat=%3Cproquest_cross%3E2784839263%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2784839263&rft_id=info:pmid/36883371&rft_doaj_id=oai_doaj_org_article_c5e2c260b54845e1b8297de267718e84&rfr_iscdi=true |